STXBP1 overexpressing mouse and its uses in screening of treatments for neuropsychiatric illness

• US 9,267,151 B2
• Filed: 08/18/2009
• Issued: 02/23/2016
• Est. Priority Date: 08/20/2008
• Status: Active Grant

• Current Assignee: Brainco Biopharma, S.L., Universidad Del Pais Vasco - Euskal Herriko Unibertsitatea
• Original Assignee: Brainco Biopharma, S.L., Universidad Del Pais Vasco - Euskal Herriko Unibertsitatea
• Inventors: Guerrero Martinez, Maria Jose, Simon Buela, Laureano, Ferrer-Alcon, Marcel, Martinez Martinez, Antonio, Meana, Jose Javier, Callado, Luis Felipe, Uriguen, Leyre
• Primary Examiner(s): Wilson, Michael
• Application Number:
  US13/059,938
• Publication Number:
  US 20110268747A1
• Time in Patent Office: 2,380 Days
• Field of Search: 800/3, 800/8, 800/18, 800/21
• US Class Current: 1/1
• CPC Class Codes: A01K 2217/052 inducing gain of function
• CPC Class Codes: A01K 2227/105 Murine
• CPC Class Codes: A01K 2267/03 Animal model, e.g. for test or diseases
• CPC Class Codes: A01K 67/027 New or modified breeds of vertebrates
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: C12N 15/8509 for producing genetically modified animals, e.g. transgenic

Abstract

A non-human transgenic animal having a polynucleotide encoding an STXBP1 polypeptide, which polynucleotide is operably linked to a promoter, wherein said transgenic animal has greater than wild-type expression of the STXBP1 polypeptide in at least one brain region, as well as related vectors, methods of producing transgenic animals, in vitro and in vivo screening methods for potential therapeutic agents, and methods for treating and diagnosing neuropsychiatric illness are disclosed.

Claims

1. A transgenic mouse whose genome comprises a polynucleotide encoding a syntaxin-binding protein 1 (STXBP1) polypeptide having at least 90% sequence identity with SEQ ID NO:

2 operably linked to an excitatory amino acid transporter 3 (EAAT3) promoter, wherein said transgenic mouse has greater than wild-type expression of the STXBP1 polypeptide in at least its brain cortex, and wherein the transgenic mouse exhibits one or more behaviours selected from the group consisting of reduced motor activity in an open field test, reduced time spent in open arms of an elevated plus maze, reduced social interaction, increased recognition index in a novel object recognition task, and decreased prepulse inhibition of startle response.

2. The transgenic mouse according to claim 1, wherein said polynucleotide is present in a higher than wild-type copy number.

3. The transgenic mouse according to claim 1, wherein said polynucleotide encodes an STXBP1 polypeptide having the amino acid sequence of SEQ ID NO:

2.

4. The transgenic mouse according to claim 1, wherein the EAAT3 promoter comprises a polynucleotide having at least 80% nucleic acid sequence identity to the sequence of SEQ ID NO:

6 or a polynucleotide having the sequence of SEQ ID NO;

6.

5. The transgenic mouse according to claim 1, having at least 10% greater expression of the STXBP1 polypeptide in said at least brain cortex, as measured by Western blot, immunofluorescence or qPCR of an STXBP1 mRNA.

6. A method of producing the transgenic mouse of claim 1, comprising:

introducing a vector comprising a polynucleotide encoding a syntaxin-binding protein 1 (STXBP1) polypeptide having at least 90% sequence identity with SEQ ID NO;

2 operably linked to an excitatory amino acid transporter 3 (EAAT3) promoter and optionally further regulatory sequences into one or more cells of the mouse at an embryonic stage, such that the transgenic mouse of claim 1 is obtained.

7. The method of claim 6, wherein the EAAT3 promoter comprises a polynucleotide having at least 80% nucleic acid sequence identity to the sequence of SEQ ID NO:

6 or a polynucleotide having the sequence of SEQ ID NO;

6.

8. The method according to claim 6, wherein said polynucleotide encodes

an STXBP1 polypeptide having the amino acid sequence of SEQ ID NO:

2.

9. The method of claim 6, further comprising extracting DNA from the mouse to confirm the incorporation of the polynucleotide into the genome of the mouse.

10. An in vivo method for identifying an agent that reduces the presence or severity of one or more behaviours in a mouse, said one or more behaviours being selected from the group consisting of reduced motor activity in an open field test, reduced time spent in open arms of an elevated plus maze, reduced social interaction, increased recognition index in a novel object recognition task, and decreased prepulse inhibition of startle response, the method comprising:

a) administering a test agent to the transgenic mouse of claim 1; and

b) subsequently assessing the presence or severity of said one or more behaviours;

wherein a reduction in said one or more behaviours relative to the same one or more behaviours in a control transgenic mouse of claim 1 that has not been administered the test agent indicates that the test agent reduces the presence or severity of the one or more behaviours in the mouse.